1 June 1997 in Annals of Oncology
The pattern and prognostic factors of delayed nausea and vomiting induced by moderately emetogenic chemotherapy have not yet been adequately studied. Data are derived from a large and well defined population of patients studied to evaluate the efficacy and tolerability of granisetron, dexamethasone and their combination in the control of acute emesis over repeated cycles of moderately emetogenic chemotherapy. Patients were monitored on days 2–5 without receiving any prophylactic treatment for delayed emesis. There were 395 evaluable patients at the first, 352 at the second and 319 at the third cycle of chemotherapy. Overall, 32.7% patients suffered symptoms of delayed vomiting and/or moderate-severe nausea at the first, 32.1% at the second and 35.1% at the third cycle of chemotherapy. More precisely, the incidence of delayed vomiting was 21.3% at the first, 18.5% at the second and 21.0% at the third cycle of chemotherapy, while the incidence of delayed moderate-severe nausea was 25.1%, 25.0% and 26.0%, respectively. The incidence of delayed vomiting and moderate-severe nausea was very low in patients who obtained good control of acute vomiting and moderate-severe nausea, but it remained substantial in patients who experienced them during the first 24 hours after chemotherapy. In fact, at first/second/third cycle of chemotherapy delayed vomiting occurred in 12.3%/11.8%/ 13.1% of patients who did not suffer from acute vomiting and in 54.1%/48.4%/55.9% of those who had acute vomiting, respectively. Similar data were obtained for delayed moderate-severe nausea. Patients without acute vomiting or moderate-severe acute nausea may not need any antiemetic prophylaxis for delayed vomiting or nausea, while those with a history of acute vomiting or moderate-severe acute nausea should always be treated for delayed emesis. Selection bias and dependence effect of delayed emesis on acute emesis can cause misinterpretation of data derived from clinical trials in patients submitted to multiple cycles of chemotherapy.
1 December 2015 in Biochemical Pharmacology
13 May 2016 in Endocrine Abstracts
Acromegaly results from excess growth hormone (GH) secretion, due to a pituitary adenoma. Surgery is the first option recommended for treatment of GH secreting pituitary adenomas; medical therapy, mostly represented by somatostatin analogues (SSA), is most often used if surgery is not successful. Insulin-like Growth Factor-1 (IGF-1) physiologically reduces GH levels through an endocrine negative feedback loop. IGF-1 exerts its effects also through PI3K/Akt/mTOR pathway activation and regulates different cellular processes. The aim of this study is to understand whether PI3K/Akt/mTOR pathway can influence IGF-1 feed-back in a rat pituitary adenoma cell line (GH3 cells). We used three inhibitors: Everolimus (mTOR inhibitor), NVP-BEZ235 (mTOR and PI3K inhibitor) and LY294002 (PI3K inhibitor) in the presence or in the absence of IGF-1. We evaluated cell viability by ATPlite Assay, GH secretion by ELISA and Akt phosphorylation by Western blot. We found that cell viability was induced by IGF-1 (+30%) and reduced by Everolimus up to 30%; this effect was not counteracted by IGF-1. NVP-BEZ235 reduced cell viability and IGF-1 counteracted this effect. GH secretion was reduced by IGF-1 (40%); this effect was not affected by Everolimus, but was blocked by NVP-BEZ235. Moreover, IGF-1 induced Akt phosphorylation, that was enhanced by Everolimus and completely abolished by NVP-BEZ235. To validate these results, we assessed LY294002 alone and with IGF-1, confirming that IGF1 increases Akt phosphorylation while LY294002 arrest this effect. These results show that IGF-1 is an important regulator of cell proliferation and GH secretion in pituitary cells and that PI3K/Akt/mTOR inhibitors may modulate IGF-1 signaling. This pathway has a role in IGF-1 negative feedback on GH secretion, through Akt inhibition. Therefore, mTOR pathway may represent a possible target for treatment of GH-secreting pituitary adenomas.
13 May 2016 in Endocrine Abstracts
Introduction: It is known that growth hormone (GH) may influence neoplastic development of endometrial epithelium. GH is produced by normal and neoplastic endometrial cells and elevated levels have been observed in endometrial epithelium of patients with endometriosis and endometrial adenocarcinoma (EA). Moreover, endometrium cancer is one of the most occurring tumors in acromegalic patients. Furthermore, autocrine GH increases the oncogenicity of EA cells and is considered fundamental in neoplastic progression. Since chemoresistance often develops in advanced EA, we aimed at investigating whether GH might influence the development of chemoresistance to drugs routinely employed in EA treatment. Description of methods: To this aim we employed two EA cell lines: HEC-1-A and AN3 CA cells. Cell viability and caspase activation were assessed by CellTiter-Glo Luminescent Cell Viability Assay (Promega) and Caspase-Glo 3/7 Assay (Promega), respectively. The expression of protein chinase C delta (PRKCD) was investigated by Western-blotting. Results: We demonstrated that GH increases the viability of EA cell lines, while doxorubicin, cisplatin and paclitaxel significantly reduce this parameter. GH was capable to blunt the effects of doxorubicin and cisplatin, but did not influence paclitaxel effects on cell viability. GH also protects EA cells from caspase activation induced by doxorubicin and cisplatin. In addition, doxorubicin and cisplatin induce PRKCD expression, an effect counteracted by GH. Conclusion: All together our results suggest that GH may contribute to EA chemoresistance by interfering with apoptotic mechanisms. This may provide new insights on novel therapies against EA chemoresistant aggressive tumors.
3 May 2017 in Endocrine Abstracts
Finding new preclinical models to study the effects of anticancer drugs is one of the aims of biomedical research. Indeed, testing different in vitro systems can lead to a better understanding of the molecular pathways regulating tumor development and growth, and help to find new therapeutic approaches. This is crucial especially in the settings of pancreatic neuroendocrine tumours (pNET), where one of the main drugs approved for medical treatment is Sunitinib, a multi-targeted receptor kinase inhibitor. Clarifying the effects of this drug may be important to develop more effective medical treatment, therefore we tested Sunitinib on the human pNET cell line, BON1, grown in two different in vitro systems, monolayer and spheroid, in order to understand the different effects of the drug in 2D and 3D settings. BON1 cells were grown in monolayer and treated with Sunitinib at increasing concentrations (0.255 μM). Cell Proliferation Assay and Luminescent Cell Viability Assay were employed to test Sunitinib antiproliferative effects. We found that Sunitinib 5 μM significantly reduced BON1 cell viability by 30% (P<0.01 vs control) after 3 days. Similarly, Sunitinib 5 μM significantly reduced BON1 cell proliferation by 50% (P<0.05 vs control) after 3 days and by 90% (P<0.05 vs control) after 7 days. Then, BON1 cells were grown in spheroids with Sunitinib at increasing concentrations (0.255 μM). Spheroids size was analyzed with ImageJ software after 3 and 7 days. We found that Sunitinib does not affect spheroid size, but induces spheroid disgregation after 7 days of treatment at 5 μM. These results indicate that measuring spheroid diameter in a 3D system is not the optimal system to assess the antiproliferative effects of Sunitinib on BON1 cells. On the other hand, the differences observed between the employed models could reflect the variations in drug response depending on cell aggregation state.